Ping Fan Chen

US Patent:

20130123237, May 16, 2013

Filed:

Feb 23, 2012

Appl. No.:

13/812536

Inventors:

Rajan Anand - Fanwood NJ, US
James M. Apgar - Highland Park NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Lin Chu - Scotch Plains NJ, US
Vincent J. Colandrea - North Brunswick NJ, US
Guizhen Dong - Dayton NJ, US
James F. Dropinski - Colts Neck NJ, US
Danqing Feng - Green Brook NJ, US
Jacqueline D. Hicks - Scotch Plains NJ, US
Jinlong Jiang - Scotch Plains NJ, US
Alexander J. Kim - Morganville NJ, US
Kenneth J. Leavitt - Plainsboro NJ, US
Bing Li - Towaco NJ, US
Xiaoxia Qian - New York NY, US
Iyassu Sebhat - Jersey City NJ, US
Lan Wei - Berkeley Heights NJ, US
Robert R. Wilkening - Maplewood NJ, US
Zhicai Wu - Montvale NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/5377
A61K 31/437
A61K 31/4985
A61K 31/351
A61K 31/397
A61K 31/4412
C07D 471/04
A61K 31/496

US Classification:

51421021, 546118, 514303, 544362, 51425304, 544127, 5142342

Abstract:

Novel compounds of structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.

US Patent:

20130203786, Aug 8, 2013

Filed:

May 16, 2011

Appl. No.:

13/643121

Inventors:

Jacqueline D. Hicks - Scotch Plains NJ, US
Tesfaye Biftu - Freehold NJ, US
Ping Chen - Edison NJ, US
Xiaoxia Qian - New York NY, US
Robert R. Wilkening - Maplewood NJ, US

International Classification:

C07D 487/04
A61K 31/506
A61K 45/06
A61K 31/519
A61K 31/437
A61K 31/4162
A61K 31/4439

US Classification:

5142641, 5483565, 514407, 514275, 544331, 5462757, 514338, 544280, 5142651, 514303, 546119, 544279

Abstract:

The present invention is directed to novel amino-substituted seven-membered heterocyclic compounds of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.

US Patent:

20140080884, Mar 20, 2014

Filed:

Jun 25, 2012

Appl. No.:

14/118998

Inventors:

Itzia Arroyo - Union NJ, US
Davida Krueger - Brooklyn NY, US
Ping Chen - Edison NJ, US
Aaron Moment - Middletown NJ, US
Tesfaye Biftu - Freehold NJ, US
Faye Sheen - Hoddesdon, GB
Yanfeng Zhang - Panan, Zhejiang, CN

Assignee:

Merck Sharp & Dohme Ltd. - Hoddesdon, Hertfordshire
Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 487/04

US Classification:

514407, 5483605

Abstract:

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.

US Patent:

57505497, May 12, 1998

Filed:

Oct 15, 1996

Appl. No.:

8/730277

Inventors:

Charles G. Caldwell - Scotch Plains NJ
Ping Chen - Old Bridge NJ
Philippe L. Durette - New Providence NJ
Paul Finke - Milltown NJ
Jeffrey Hale - Westfield NJ
Edward Holson - New York NY
Ihor Kopka - Millburn NJ
Malcolm MacCoss - Freehold NJ
Laura Meurer - Scotch Plains NJ
Sander G. Mills - Woodbridge NJ
Albert Robichaud - Stirling NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 3141
C07D25704
C07D27110

US Classification:

514364

Abstract:

The present invention is directed to certain novel compounds represented by structural formula I: ##STR1## or a pharmaceutically acceptable salt thereof, wherein R. sup. 3, R. sup. 6, R. sup. 7, R. sup. 8, R. sup. 11, R. sup. 12, R. sup. 13, A, Q, W, X, Y, Z and n are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis.

US Patent:

20230018413, Jan 19, 2023

Filed:

Aug 3, 2020

Appl. No.:

17/632065

Inventors:

- Rahway NJ, US
Ping Chen - Edison NJ, US
Dane James Clausen - Rahway NJ, US
Jinsong Hao - Belle Mead NJ, US
Dipannita Kalyani - Union NJ, US
Michael T. Rudd - Collegeville PA, US
Shawn P. Walsh - Bridgewater NJ, US
Lan Wei - Berkeley Heights NJ, US
Dexi Yang - Livingston NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 403/04
C07D 207/14
C07D 401/04
C07D 471/04
C07D 417/04
C07D 413/10
C07D 417/14
C07D 413/04
C07D 409/04
C07D 405/04
C07D 498/04
C07D 491/048

Abstract:

The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

US Patent:

20230008022, Jan 12, 2023

Filed:

Nov 25, 2019

Appl. No.:

17/295497

Inventors:

Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

US Patent:

20210380572, Dec 9, 2021

Filed:

Oct 11, 2019

Appl. No.:

17/282821

Inventors:

- Rahway NJ, US
Ping Chen - Edison NJ, US
Xavier Fradera - Brookline MA, US
Liangqin Guo - Monroe NJ, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Jongwon Lim - Lexington MA, US
Theodore A. Martinot - Southborough MA, US
Alexander Pasternak - Jamaica Plain MA, US
Li Xiao - Cranbury NJ, US
Wensheng Yu - Edison NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 413/14
C07D 401/06
C07D 401/14
C07D 413/06

Abstract:

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

US Patent:

20150099891, Apr 9, 2015

Filed:

Oct 6, 2014

Appl. No.:

14/507001

Inventors:

- Rahway NJ, US
- Hoddesdon, GB
Ping Chen - Edison NJ, US
Aaron J. Moment - Scotch Plains NJ, US
Tesfaye Biftu - Freehold NJ, US
Faye Sheen - Hoddesdon, GB
Yanfeng Zhang - Panan, CN

International Classification:

C07D 487/04

US Classification:

5483605

Abstract:

Novel crystalline forms of (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine are potent inhibitors of dipeptidyl peptidase-IV and are useful for the treatment of non-insulin dependent (Type 2) diabetes mellitus. The invention also relates to pharmaceutical compositions containing these novel forms, processes to prepare these forms and their pharmaceutical compositions as well as uses thereof for the treatment of Type 2 diabetes.